Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | May 28, 2015 at 9:30 AM EDT

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date and for the selected pharmaceutical stocks, short…

Chris Lange | May 28, 2015 at 8:25 AM EDT

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of…

Douglas A. McIntyre | May 24, 2015 at 8:22 AM EDT

Protests Against Monsanto in 400 Cities

Genetically modified organisms (GMO) are bad for people, the environment, and water supplies, at least. This is according to the…

Jon C. Ogg | May 23, 2015 at 9:30 AM EDT

The Most Loved Biotechs of Big Hedge Funds

There were some interesting positions of hedge funds in biotech, long and short, from the Goldman Sachs Hedge Fund Trend…

Lee Jackson | May 22, 2015 at 9:15 AM EDT

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug…

Jon C. Ogg | May 21, 2015 at 2:15 PM EDT

Why Baxter May Be Very Undervalued Into Breakup

If Merrill Lynch's Bob Hopkins and team are correct, Baxter International is worth a lot more than its current share…

Jon C. Ogg | May 21, 2015 at 1:40 PM EDT

How to Evaluate a 50% Move in AVEO

When investors see stocks run up 50% or more on a news release, they probably just assume the company is…

Jon C. Ogg | May 20, 2015 at 1:45 PM EDT

Has MannKind Stock Finally Bottomed Out?

After looking at the recent recovery, and after looking over the more recent news that has come out after earnings,…

Chris Lange | May 20, 2015 at 11:10 AM EDT

How Sarepta Short Interest Is Adding to Its Gains

Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to…

Chris Lange | May 20, 2015 at 9:55 AM EDT

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

Johnson & Johnson has been working on its pharmaceuticals pipeline for a while, and plans on continuing to do so.

Douglas A. McIntyre | May 20, 2015 at 6:33 AM EDT

More Than a Billion People Smoke Tobacco

In a piece of news that should hearten the cigarette industry and send chills down the spines of world health…

Chris Lange | May 19, 2015 at 2:00 PM EDT

Is This the End of the Growth Phase for Intercept?

Investors are not too happy with Intercept Pharmaceuticals after it released the terms for its most recent clinical trial.

Chris Lange | May 18, 2015 at 9:10 AM EDT

What This New Trial Means for Eleven Biotherapeutics

Eleven Biotherapeutics released its most recent clinical trial results, and its drug candidate did not meet either of its two…

Chris Lange | May 14, 2015 at 3:08 PM EDT

The 5 Winners and Losers From ASCO Presentations

Investors, doctors and cancer patients are anxiously awaiting some of the key presentations and abstracts from the American Society of…

Chris Lange | May 14, 2015 at 12:00 PM EDT

AcelRX Takes Flight With New Department of Defense Contract

AcelRX announced that it entered into a contract with the U.S. Army Medical Research and Material Command within the Department…

1 … 261 262 263 264 265 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers More Selective on Big Pharma Stocks

Short Sellers Get Even More Ambitious Against Biotech Leaders

Protests Against Monsanto in 400 Cities

The Most Loved Biotechs of Big Hedge Funds

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Why Baxter May Be Very Undervalued Into Breakup

How to Evaluate a 50% Move in AVEO

Has MannKind Stock Finally Bottomed Out?

How Sarepta Short Interest Is Adding to Its Gains

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

More Than a Billion People Smoke Tobacco

Is This the End of the Growth Phase for Intercept?

What This New Trial Means for Eleven Biotherapeutics

The 5 Winners and Losers From ASCO Presentations

AcelRX Takes Flight With New Department of Defense Contract

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Short Sellers More Selective on Big Pharma Stocks

Short Sellers Get Even More Ambitious Against Biotech Leaders

Protests Against Monsanto in 400 Cities

The Most Loved Biotechs of Big Hedge Funds

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

Why Baxter May Be Very Undervalued Into Breakup

How to Evaluate a 50% Move in AVEO

Has MannKind Stock Finally Bottomed Out?

How Sarepta Short Interest Is Adding to Its Gains

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

More Than a Billion People Smoke Tobacco

Is This the End of the Growth Phase for Intercept?

What This New Trial Means for Eleven Biotherapeutics

The 5 Winners and Losers From ASCO Presentations

AcelRX Takes Flight With New Department of Defense Contract

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how